Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities

Medtronic, Inc. (mdt) PT Raised to $107 at Evercore ISI

Evercore ISI analyst Vijay Kumar raised the price target on Medtronic, Inc. (NYSE: mdt) to $107.00 (from $106.00) while maintaining a Outperform rating.

The analyst comments "Thesis Update: Im in the EU & thought the Caesars phrase (w some tweaks) was apt in... More

TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $106.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "MDT reported F1Q'26 adjusted revenue of $8.54B with underlying organic growth of 4.8%. Reported revenue exceeded the $8.38B consensus target,... More

Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT)

Truist Securities analyst Richard Newitter reiterated a Hold rating and $92.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "MDT's 4.8% organic rev growth was roughly in-line with 4.9% CNS, while higher reported rev (on FX) and (+$0.02 non-op items) drove a slight EPS beat ($1.26 vs CNS $1.23) on roughly... More

Goldman on Medtronic, Inc. (MDT), 'believe investors had expected total organic growth acceleration to follow the strong performance in CAS'

Goldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT)

The analyst comments "This morning, Medtronic reported 1QFY26 that on a reported basis exceeded both GSe/Consensus (Visible Alpha consensus Data, unless otherwise noted). On an... More

Raymond James on Medtronic, Inc. (MDT) Earnings: 'All in, this result and guide fell short of our elevated expectations'

Raymond James analyst Jayson Bedford reiterated a Market Perform rating and {REMOVEPT} price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "F1Q revenue beat consensus (by ~2%), but this was due to FX and Other revenue as organic growth of 4.8% y/y... More

Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)

Stifel analyst Rick Wise reiterated a Hold rating and $87.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "Reporting yet another largely as expected quarter, F1Q26 performance was positively just above Consensus for both organic growth and EPS...and this... More

Mizuho on Medtronic, Inc. (MDT): 'Largely Inline Print Likely Overshadowed by New Board Appointees'

Mizuho analyst Anthony Petrone reiterated an Outperform rating and $100.00 price target on Medtronic, Inc. (NYSE: MDT)

The analyst comments "MDT reported a +$195mn/+$0.03 beat driven by strong performances across Cardiovascular (+$92mn ahead of Street), Diabetes (+22mn ahead of Street) and MedSurg... More

Medtronic (MDT) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance

Medtronic (NYSE: MDT) reported Q1 EPS of $1.26, $0.03 better than the analyst estimate of $1.23. Revenue for the quarter came in at $8.6 billion versus the consensus estimate of $8.38 billion.

GUIDANCE:

Medtronic sees FY2026 EPS of $5.60-$5.66, versus the consensus of $5.55.

For earnings history and earnings-related data on Medtronic (MDT) click here.